Clinical Trial Update: A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing daily versus thrice-weekly Trimethoprim/Sulfamethoxazole for Pneumocystis jirovecii pneumonia prophylaxis in HIV-infected pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Pneumocystis Pneumonia

Drugs mentioned

• Trimethoprim-sulfamethoxazole (trimethoprim-sulfamethoxazole)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections | Phase 3 | Status: COMPLETED